mRNA-4157,Pembrolizumab
Moderna,Merck
['mrna-4157', 'moderna']
we re excited to join the 2023 annual meeting and present two abstracts from phase 2 data on mrna-4157 (v940), an investigational #mrna individualized neoantigen therapy. #teammoderna will be at booth 22145 stop by and say hello! learn more: 
Our mission is to deliver the greatest possible impact to people through mRNA medicines.